News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Neurosearch A/S (NEUR.CO) Announces New Findings From the MermaiHD Phase III Study Supporting Potential Disease Modifying Properties of Huntexil(R)


3/8/2010 11:49:17 AM

COPENHAGEN and BALLERUP, Denmark, March 8, 2010 (GLOBE NEWSWIRE) -- NeuroSearch (NEUR) today announced that further analysis of the data from the MermaiHD study with Huntexil(R) (pridopidine) for the treatment of Huntington's disease supports potential disease modifying properties of the drug.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES